[go: up one dir, main page]

NO20015383D0 - Nye forbindelser - Google Patents

Nye forbindelser

Info

Publication number
NO20015383D0
NO20015383D0 NO20015383A NO20015383A NO20015383D0 NO 20015383 D0 NO20015383 D0 NO 20015383D0 NO 20015383 A NO20015383 A NO 20015383A NO 20015383 A NO20015383 A NO 20015383A NO 20015383 D0 NO20015383 D0 NO 20015383D0
Authority
NO
Norway
Prior art keywords
new connections
connections
new
Prior art date
Application number
NO20015383A
Other languages
English (en)
Other versions
NO20015383L (no
NO321377B1 (no
Inventor
Marcel Linschoten
Magnus Polla
Peder Svensson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20015383D0 publication Critical patent/NO20015383D0/no
Publication of NO20015383L publication Critical patent/NO20015383L/no
Publication of NO321377B1 publication Critical patent/NO321377B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
NO20015383A 1999-05-03 2001-11-02 Nye forbindelser NO321377B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9901573A SE9901573D0 (sv) 1999-05-03 1999-05-03 New compounds
PCT/SE2000/000834 WO2000066557A1 (en) 1999-05-03 2000-05-03 New compounds

Publications (3)

Publication Number Publication Date
NO20015383D0 true NO20015383D0 (no) 2001-11-02
NO20015383L NO20015383L (no) 2001-12-21
NO321377B1 NO321377B1 (no) 2006-05-02

Family

ID=20415426

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015383A NO321377B1 (no) 1999-05-03 2001-11-02 Nye forbindelser

Country Status (27)

Country Link
US (1) US7071175B1 (no)
EP (1) EP1180098A1 (no)
JP (1) JP2002543184A (no)
KR (1) KR100755152B1 (no)
CN (1) CN1263739C (no)
AR (1) AR034241A1 (no)
AU (1) AU771760B2 (no)
BR (1) BR0010257A (no)
CA (1) CA2371213C (no)
CZ (1) CZ20013930A3 (no)
EE (1) EE04490B1 (no)
HK (1) HK1042303A1 (no)
HU (1) HUP0202876A3 (no)
IL (1) IL145954A0 (no)
IS (1) IS6139A (no)
MX (1) MXPA01011055A (no)
MY (1) MY128014A (no)
NO (1) NO321377B1 (no)
NZ (1) NZ515062A (no)
PL (1) PL200932B1 (no)
RU (1) RU2244708C2 (no)
SE (1) SE9901573D0 (no)
SK (1) SK15462001A3 (no)
TR (1) TR200103153T2 (no)
TW (1) TWI232105B (no)
WO (1) WO2000066557A1 (no)
ZA (1) ZA200108968B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828566B2 (en) * 1997-07-22 2004-12-07 Hitachi Ltd Method and apparatus for specimen fabrication
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
BR0014615A (pt) 1999-09-14 2002-06-18 Meiji Seika Kaisha Derivado de ácido fosfÈnico que apresenta atividade inibidora contra carboxipeptidase b
US7214831B2 (en) 2002-05-22 2007-05-08 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-chalcogenmethylcarbonyl compounds
SE0103272D0 (sv) 2001-09-28 2001-09-28 Astrazeneca Ab Chemical compounds
US6713496B2 (en) 2002-01-22 2004-03-30 Pfizer Inc 3-(imidazolyl)-2-alkoxypropanoic acids
MXPA04005940A (es) 2002-01-22 2004-09-13 Pfizer Acidos 3-(imidazolil)-2-aminopropanoicos.
EP2204373A1 (en) * 2002-03-21 2010-07-07 Bayer Schering Pharma Aktiengesellschaft Phosphonic acid as Plasma Carboxypeptidase B Inhibitors
SE0201837D0 (sv) * 2002-06-14 2002-06-14 Astrazeneca Ab Chemical compounds
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
CN102216276A (zh) 2008-09-11 2011-10-12 辉瑞大药厂 取代的杂芳基物
JPWO2010050525A1 (ja) 2008-10-29 2012-03-29 大正製薬株式会社 ＴＡＦＩａ阻害活性を有する化合物
EP2389374A1 (en) 2009-01-20 2011-11-30 Pfizer Inc. Substituted pyrazinone amides
JP5086480B2 (ja) 2009-03-11 2012-11-28 ファイザー・インク グルコキナーゼ活性化剤として使用されるベンゾフラニル誘導体
WO2011087822A1 (en) 2009-12-22 2011-07-21 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
CN102249992A (zh) * 2011-07-05 2011-11-23 广东工业大学 一种制备2-氨基异烟酸的方法
CN103987664B (zh) 2011-12-06 2017-03-08 德尔塔阀门公司 龙头中的臭氧分配
BR112015029667A2 (pt) 2013-06-10 2017-07-25 Sanofi Sa derivados de ureia macrocíclica como inibidores de tafia, sua preparação e seus usos como produtos farmacêuticos
AR099134A1 (es) * 2014-01-24 2016-06-29 Hoffmann La Roche Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina
WO2017112795A1 (en) 2015-12-21 2017-06-29 Delta Faucet Company Fluid delivery system including a disinfectant device
USD879309S1 (en) 2018-08-09 2020-03-24 Scott Specialties, Inc. Maternity support

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3091569A (en) 1960-08-26 1963-05-28 Mead Johnson & Co Mucolytic-nu-acylated sulfhydryl compositions and process for treating animal mucus
FR1393338A (fr) 1964-01-08 1965-03-26 Rech S Pharma Et Scient Nouveau dérivé de la cystéine et sa préparation
US3766206A (en) 1971-11-03 1973-10-16 Pfizer 18beta-glycyrrheting acid amides useful as antiulcer agents
FR2266502A1 (en) 1974-04-08 1975-10-31 Synpharm Sa N-(2-thenoyl)-cysteine and esters - with mucolytic activity, prepd. from cysteine (esters) and thenoyl chloride
US4177277A (en) 1977-01-17 1979-12-04 E. R. Squibb & Sons, Inc. Method for alleviating hypertension
US4113715A (en) 1977-01-17 1978-09-12 E. R. Squibb & Sons, Inc. Amino acid derivatives
JPS545949A (en) 1977-06-16 1979-01-17 Hisamitsu Pharmaceut Co Inc Novel cyclohexanecarboxylic acid and its derivatives
FR2430945A2 (fr) 1978-07-12 1980-02-08 Chauvin Blache Lab Nouveaux derives de la cysteine, leur procede de fabrication et leur application en therapeutique
US4537727A (en) 1982-11-12 1985-08-27 Eli Lilly And Company Process for recovering 2-acetylthiomethyl-5-aminopentanoic acid
EP0136883B1 (en) 1983-10-03 1987-11-25 E.R. Squibb & Sons, Inc. Enkephalinase inhibitors
WO1986004580A1 (fr) * 1985-02-08 1986-08-14 Takeda Chemical Industries, Ltd. Derives de piperidine
US4708965A (en) 1985-09-16 1987-11-24 Morgan Lee R Method of treating herpes virus infections with N,N'-diacetylcystine and derivatives
JPS62270555A (ja) * 1986-05-19 1987-11-24 Dainippon Pharmaceut Co Ltd スルホン酸誘導体およびその塩
EP0318859A3 (en) 1987-12-03 1990-08-16 Dainippon Pharmaceutical Co., Ltd. N-substituted mercaptopropanamide derivatives
JPH01254654A (ja) * 1988-04-01 1989-10-11 Dainippon Pharmaceut Co Ltd スルホン酸の誘導体及びその塩
EP0361365A1 (en) * 1988-09-30 1990-04-04 E.R. SQUIBB & SONS, INC. Aminobenzoic and aminocyclohexane-carboylic acid compounds, compositions, and their method of use
DE3838467C2 (de) 1988-11-12 1998-12-10 Agfa Gevaert Ag Fotografisches Aufzeichnungsmaterial
IE910818A1 (en) 1990-08-09 1992-02-12 Sankyo Co (benzhydryloxyethylpiperidyl)aliphatic acid derivatives and¹their use in the treatment of allergies and asthma
IT1249650B (it) 1991-05-29 1995-03-09 Poli Ind Chimica Spa N-(5-tioxo-l-prolil)-l-cisteina e suoi derivati, loro preparazione ed impiego terapeutico
GB9122016D0 (en) 1991-10-16 1991-11-27 Glaxo Group Ltd Chemical compounds
IT1266571B1 (it) * 1993-07-30 1997-01-09 Zambon Spa Derivati della beta-mercapto-propanammide utili nel trattamento delle malattie cardiovascolari
US5470834A (en) * 1993-10-06 1995-11-28 Florida State University Sulfoximine and suldodiimine matrix metalloproteinase inhibitors
DE4441873A1 (de) * 1994-11-24 1996-05-30 Wella Ag Mittel zur dauerhaften Haarverformung
JP3874455B2 (ja) * 1996-06-27 2007-01-31 新日本製鐵株式会社 フィブリノーゲン受容体拮抗物質およびそれを有効成分とする医薬製剤

Also Published As

Publication number Publication date
PL354360A1 (en) 2004-01-12
CA2371213A1 (en) 2000-11-09
CA2371213C (en) 2009-11-10
HK1042303A1 (zh) 2002-08-09
EP1180098A1 (en) 2002-02-20
NZ515062A (en) 2004-04-30
TR200103153T2 (tr) 2002-04-22
KR100755152B1 (ko) 2007-09-04
TWI232105B (en) 2005-05-11
NO20015383L (no) 2001-12-21
EE200100574A (et) 2003-02-17
WO2000066557A1 (en) 2000-11-09
SK15462001A3 (sk) 2002-11-06
ZA200108968B (en) 2003-09-05
IL145954A0 (en) 2002-11-10
JP2002543184A (ja) 2002-12-17
CN1263739C (zh) 2006-07-12
HUP0202876A2 (hu) 2003-01-28
IS6139A (is) 2001-11-01
MXPA01011055A (es) 2002-06-04
US7071175B1 (en) 2006-07-04
MY128014A (en) 2007-01-31
AU771760B2 (en) 2004-04-01
CN1358174A (zh) 2002-07-10
CZ20013930A3 (cs) 2002-10-16
BR0010257A (pt) 2002-02-13
RU2244708C2 (ru) 2005-01-20
SE9901573D0 (sv) 1999-05-03
PL200932B1 (pl) 2009-02-27
AU4790200A (en) 2000-11-17
AR034241A1 (es) 2004-02-18
EE04490B1 (et) 2005-06-15
HUP0202876A3 (en) 2005-07-28
NO321377B1 (no) 2006-05-02
KR20020010630A (ko) 2002-02-04

Similar Documents

Publication Publication Date Title
NO20014518L (no) Nye forbindelser
DK1202994T3 (da) Nye forbindelser
NO20021436L (no) Nye forbindelser
NO20026064L (no) Nye forbindelser
NO20023933L (no) Nye forbindelser
NO20033715D0 (no) Nye sammensetninger
NO20020810L (no) Nye fenylpiperaziner
NO20016115D0 (no) Substituerte heterocykelkondenserte gamma-karboliner
NO20015383L (no) Nye forbindelser
NO20025151D0 (no) Nye forbindelser
NO20015074L (no) Nye sammensetninger
NO20031141D0 (no) Nye forbindelser
DK1237857T3 (da) Nye Phenalkyloxyphenylderivater
NO20010860D0 (no) Nye forbindelser
NO20026162D0 (no) Nye forbindelser
NO20010861D0 (no) Nye forbindelser
NO20026081D0 (no) Nye forbindelser
NO20030274D0 (no) Nye aryleten-sulfonamider
NO20015374D0 (no) Nye forbindelser
NO995945D0 (no) Nye forbindelser
NO20022927D0 (no) Substituerte pyrrazoler
NO20014629L (no) Nye forbindelser
NO20016273L (no) Nye forbindelser
NO20010584D0 (no) Nye forbindelser
NO20011262D0 (no) Nye forbindelser

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees